Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › trametinib

trametinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of trametinib

29 trials tracked of trametinib: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 415 citations.

29Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 4 Phase 2 23 Phase 1 1 Other / NA 1
  1. Phase 3 Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). Completed · 415 cited
  2. Phase 3 Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes Completed · 30 cited
  3. Phase 3 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma Completed
  4. Phase 3 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Completed
  5. Phase 2 Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer Completed
  6. Phase 2 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Completed
Show 23 more trials
  1. Phase 2 Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Completed
  2. Phase 2 Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) Completed
  3. Phase 2 Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery Completed
  4. Phase 2 Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma Completed
  5. Phase 2 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed
  6. Phase 2 Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors Completed
  7. Phase 2 An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread Completed
  8. Phase 2 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed
  9. Phase 2 BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) Completed
  10. Phase 2 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Completed
  11. Phase 2 Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Completed
  12. Phase 2 A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Completed
  13. Phase 2 A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC Completed
  14. Phase 2 Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations Completed
  15. Phase 2 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Completed
  16. Phase 2 A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) Completed
  17. Phase 2 Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. Completed
  18. Phase 2 Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer Completed
  19. Phase 2 MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations Completed
  20. Phase 2 Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain Completed
  21. Phase 2 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma Completed
  22. Phase 1 Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Completed
  23. N/A Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Dabrafenib and trametinib produce rapid response in a single case of BRAF V600E-mutant PHC
Oncology Sys. Review
Dabrafenib and trametinib produce rapid response in a single case of BRAF V600E-mutant PHC Targeted Treatment Shows Promise for Rare Pancreatic Cancer Type
This systematic review and case report analyze pancreatic hepatoid carcinoma (PHC) and the role of targeted therapies. The analysis identifi…
A specific drug combination showed a rapid and deep response in a patient with a rare type of pancreatic cancer involving a BRAF mutation.
Frontiers Aug 19, 2026
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
Oncology Cohort
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies Can a simple test find the right drug to save children with tough leukemia?
A prospective, multicenter Drug Response Profiling registry of 340 children with relapsed or refractory acute lymphoblastic leukemia in 17 E…
A simple test matching leukemia drugs to patient cells helped 68% of children respond to treatment and gave 28 of 42 patients a chance to su…
medRxiv Apr 16, 2026